Mark Barakat, MD

Barakat is founder and director of research at Retina Macula Institute of Arizona in Scottsdale, Arizona, and medical director of Spectra Eye Institute in Sun City, Arizona, USA. He is a clinical assistant professor of ophthalmology at the University of Arizona College of Medicine – Phoenix and a fellow of the American Academy of Ophthalmology and the American Society of Retina Specialists.

Financial disclosures: He reports being a consultant for AbbVie, Adverum Biotech, Alcon, Alkeus, ANI Pharmaceuticals, Annexon, Apellis, Astellas, Bausch + Lomb, Beacon, Biocryst, Boehringer Ingelheim, Celltrion, Cencora, Clearside Biomedical, EyePoint Pharma, Genentech, Glaukos, Kodiak Sciences, Harrow, Janssen, Neurotech, Ocular Therapeutix, Oculis, Opthea, Outlook Therapeutics, Palatin Technologies, Regeneron, RegenxBio, RetinAI, RevOpsis Therapeutics, Roche, Sanofi, Stealth Biotherapeutics and Surrozen; being an investigator for 4DMT, Adverum Biotech, Annexon Biosciences, Beacon, Boehringer Ingelheim, Clearside Biomedical, EyeBio, EyePoint Pharma, Genentech, Glaukos, Kanghong/Vanotech, Kodiak Sciences, Ocular Therapeutix, Oculis, Opthea, Perceive Bio, Perfuse, Regeneron, RegenxBio, Roche and Stealth Biotherapeutics; being a speaker for Alcon, ANI Pharmaceuticals, Apellis, Astellas, Genentech and Regeneron; and having stock/stock options in NeuBase, Oxurion and RevOpsis Therapeutics.